Neuroprotection for Parkinson's disease: A new approach for a new millennium

Expert Opinion on Investigational Drugs

Volumn 10, Issue 10, 2001, Pages 1855-1868

  Drukarch, B ^a   Van Muiswinkel, F L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Basal ganglia; Detoxification enzymes; Gene induction; Neurodegeneration; Neuromelanin; Neuroprotection; Oxidative stress; Parkinson's disease; Quinone; Substantia nigra

Indexed keywords

2 (3) TERT BUTYL 4 HYDROXYANISOLE; ACYLTRANSFERASE; ANETHOLEDITHIOTHIONE; BUTYLATED HYDROXYANISOLE; DIMERCAPROL; DITHIOLETHIONE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; EPIGALLOCATECHIN GALLATE; EPOXIDE HYDROLASE; FUMARIC ACID DIMETHYL ESTER; GLUTATHIONE; GLUTATHIONE TRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOTHIOCYANIC ACID DERIVATIVE; LEVODOPA; MESSENGER RNA; METHYL 3 PHENYLPROPENOATE; NEUROMELANIN; OLTIPRAZ; OXYGEN RADICAL; PEROXIDASE; PHENOL DERIVATIVE; POLYPHENOL DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFORAPHANE; THIOCTIC ACID; THIOL DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICINAL DITHIOLE;

APOPTOSIS; AUTOOXIDATION; CELL DEATH; CHEMICAL REACTION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DETOXIFICATION; DISEASE COURSE; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG STRUCTURE; DRUG THERAPY; EVALUATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOCHONDRION; MORBIDITY; MORTALITY; NEUROPROTECTION; PARKINSON DISEASE; PATHOGENESIS; PATHOGENICITY; REVIEW; STIMULATION; SUBSTANTIA NIGRA;

ANIMALS; DISEASE PROGRESSION; HUMANS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 0034780362     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.10.1855     Document Type: Review

References (106)

1. Genetic influence on the development of Parkinson's disease
2. Gastrointestinal dysfunction in Parkinson's disease
3. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific
4. Genetics of Parkinson's disease
5. Parkinson's disease in twins: An etiologic study
6. The early diagnosis of Parkinson' disease
7. Epidemiology versus genetics in Parkinson's disease: Progress in resolving an age-old debate
8. Etiology and pathogenesis of Parkinson's disease
9. Chronic systemic pesticide exposure reproduces features of Parkinson's disease
10. Alzheimer's disease and Parkinson's disease; distinct entities or extremes of a spectrum of neurodegeneration?
11. Melanized dopaminergic neurones are differentially susceptible to degeneration in Parkinson's disease
12. Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menschen
13. Biochemistry of the extrapyramidal system
14. Der L-dioxyphenylalanine
15. Aromatic amino acids and modification of parkinsonism
16. History of levodopa and dopamine agonists in Parkinson's disease treatment
17. Therapeutic advances in idiopathic parkinsonism
18. Success and problems of long-term levodopa therapy in Parkinson's disease
19. Prospects for new restorative and neuroprotective treatments in Parkinson's disease
20. Apoptosis modulators in the therapy of neurodegenerative diseases
21. Remacemide: Current status and clinical applications
22. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
23. Understanding cell death in Parkinson's disease
24. Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease
25. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: Neuroprotective strategies
26. Drug treatment of Parkinson's disease: Time for phase II
27. Parkinson's disease: A major hypokinetic basal ganglia disorder
28. Iron, aging, and human disease: Historical background and new hypotheses
29. A multicenter controlled clinical trial in early Parkinson disease
30. Parkinson's disease: Prospects for improved drug therapy
31. Pharmacology and neuroprotective properties of rasagiline
32. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B
33. Enzymatic oxidation of dopamine: The role of prostaglandin H synthase
34. Cytotoxic and genotoxic potential of dopamine
35. Tyrosinase mRNA is expressed in human substantia nigra
36. Prostaglandin H synthase-mediated metabolism of dopamine: Implication for Parkinson's disease
37. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: Possible mechanisms of formation involving reactive oxygen species
38. Biochemical and toxicological properties of the oxidation products of catecholamines
39. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones
40. The oxidative metabolism of catecholamines in the brain: A review
41. Biosynthesis, structure, and function of neuromelanin and its relation to Parkinson's disease: A critical update
42. The neuromelanin of the human substantia nigra
43. Iron- and peroxide-dependent conjugation of dopamine with cysteine: Oxidative routes to the novel brain metabolite 5-S-cysteinyldopamine
44. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles
45. Protection of intracellular dopamine cytotoxicity by dopamine disposition and metabolism factors
46. Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurones: Potential sites for somatodendritic storage and release of dopamine
47. Low numbers and no loss of melanized nigral neurones with increasing age in normal human brain in India
48. Endogenous glutathione conjugates: Occurrence and biological functions
49. 3 and oxidation of dopamine to aminochrome
50. Metabolic activation of dopamine o-quinones to o-semiquinone by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects
51. Superoxide dismutase and catalase enhance autooxidation during one-electron reduction of aminochrome by NADPH-cytochrome P-450 reductase
52. Glutathione
53. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation
54. NADPH cytochrome P-450 reductase in rat, mouse and human brain
55. Some aspects of tyrosine secondary metabolism
56. Cytochrome P450: Structure, function, and generation of reactive oxygen species
57. Overview of enzymes of drug metabolism
58. Detoxification enzymes and chemoprevention
59. DT-diaphorase as a quinone reductase: A cellular control device against semiquinone and superoxide radical formation
60. On the mechanism of the Mn3+-induced neurotoxicity of dopamine: Prevention of quinone-derived oxygen toxicity by DT diaphorase and superoxide dismutase
61. Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism
62. Pro- and antioxidant functions of quinones and quinone reductases in mammalian cells
63. Preferential expression of superoxide dismutase messenger RNA in melanized neurones in human mesencephalon
64. Glutathione transferases catalyze the detoxification of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes
65. Human class Mu glutathione transferases, in particular isoenzyme M2-2, catalyze detoxification of the dopamine metabolite aminochrome
66. Histochemical detection of quinone reductase activity in situ using LY 83583 reduction and oxidation
67. Distribution of DT diaphorase in the rat brain: Biochemical and immunohistochemical studies
68. Chemical and molecular regulation of enzymes that detoxify carcinogens
69. Antioxidant-inducible genes
70. On the mechanisms of induction of cancer-protective enzymes: A unifying proposal
71. Cellular response to cancer chemopreventive agents: Contribution of the antioxidant responsive element to the adaptive response to oxidative and chemical stress
72. Chemoprotective 3H-1,2-dithiole-3-thione induces antioxidant genes in vivo
73. Reactive oxygen species-related induction of multidrug resistance-associated protein 2 expression in primary hepatocytes exposed to sulforaphane
74. Regulatory mechanisms of monofunctional and bifunctional anticarcinogenic enzyme inducers in murine liver
75. Aryl hydrocarbon receptor-mediated signal transduction
76. Molecular biology of the aromatic hydrocarbon (dioxin) receptor
77. Potency of michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups
78. The potency of inducers of NAD(P)H:(quinone-acceptor) oxidoreductase parallels their efficiency as substrates for glutathione transferases: Structural and electronic correlations
79. Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis
80. Redox regulation of genes that protect against carcinogens
81. Antioxidant response element
82. Antioxidant regulation of genes encoding enzymes that detoxify xenobiotics and carcinogens
83. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain
84. Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2-related factor 2
85. Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism
86. Signal transduction events elicited by natural products: Role of MAPK and caspase pathways in homeostatic response and induction of apoptosis
87. Chemoprevention: Increased potential to bear fruit
88. The Nrf2 transcription factor contributes both to the basal expression of glutathione S-transferases in mouse liver and to their induction by the chemopreventive synthetic antioxidants, butylated hydroxyanisole and ethoxyquin
89. The cap'n'collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes
90. An important function of Nrf2 in combating oxidative stress: Detoxification of acetaminophen
91. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice
92. Coordinate regulation of NAD(P)H: Quinone oxidoreductase and glutathione-S-transferases in primary cultures of rat neurones and glia: Role of the antioxidant/electrophile responsive element
93. Preferential expression of antioxidant response element mediated gene expression in astrocytes
94. Astrocyte-mediated enhancement of neuronal survival is abolished by glutathione deficiency
95. Astrocyte-enhanced neuronal survival is mediated by scavenging of extracellular reactive oxygen species
96. Alpha-lipoic acid, alike anethole dithiolethione, but in contrast to N-acetylcysteine stimulates endogenous antioxidant pathways in cultured astroglial cells
97. Anethole dithiolethione, a putative neuroprotectant, increases intracellular and extracellular glutathione levels during starvation of cultured astroglial cells
98. Anethole dithiolethione prevents oxidative damage in glutathione-depleted astrocytes
99. Anethole dithiolethione: Biochemical considerations
100. Assessment of the role of the glutathione and pentose phosphate pathway in the protection of primary cerebrocortical cultures from oxidative stress
101. Activation of endogenous antioxidant defenses in neuronal cells prevents free radical-mediated damage
102. Metabolism of xenobiotics in the central nervous system: Implications and challenges
103. Molecular events in neurodegeneration and neuroprotection in Parkinson's disease and its MPTP model as assessed by cDNA microarray
104. Nuclear factor-κB is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms
105. Inhibition of NF-κB activation in human T-cell lines by anetholdithiolthione
106. Involvement of NF-κB in the induction of NAD(P)H: Quinone oxidoreductase (DT-diaphorase) by hypoxia, oltipraz and mitomycin C